iMDx GraftAssure Assay and Kidney-Graft-Saving Drug Publication
The new study published in The Lancet Regional Health – Europe highlights the potential use of donor-derived cell-free DNA monitoring to assist in treatment decisions for kidney transplant patients, possibly guiding the use of a drug that could save kidney grafts.
NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new study in The Lancet Regional Health – Europe, part of the Lancet Group, demonstrating the potential role of donor-derived cell-free DNA (dd-cfDNA) monitoring to help guide treatment decisions for kidney transplant patients.